
Aug 23, 2025, 22:35
LOCKTAC Molecular Glues Are Changing the Rules of Drug Discovery – Amgen
Amgen shared a post on X:
“Amgen’s LOCKTAC molecular glues are changing how we target disease.
AMG 193, now in clinical trials, is designed to lock PRMT5 to MTA in MTAP-deleted tumors.
Read more about how Amgen is working to innovate in this space.”
More posts featuring Amgen on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 24, 2025, 01:32
Aug 23, 2025, 22:57
Aug 23, 2025, 22:35
Aug 23, 2025, 22:10
Aug 23, 2025, 21:42
Aug 23, 2025, 21:31
Aug 23, 2025, 20:55
Aug 23, 2025, 20:22